Regulation of successful optic nerve regeneration by the mevalonate/cholesterol pathway

甲羟戊酸/胆固醇途径成功调节视神经再生

• 批准号: 10500994
• 负责人: Matthew B Veldman
• 金额: $ 40.38万
• 依托单位: MEDICAL COLLEGE OF WISCONSIN
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10500994
• 关键词: Acute; Affect; American; Animal Model; Animals; Axon; Biological; Blindness; Brain; Cell Survival; Cells; Chemicals; Cholesterol; Coenzyme Q10; Data; Data Set; Disease model; Drug Combinations; Exhibits; Failure; Financial Hardship; Future; Gene Expression; Gene Transfer; Genes; Genetic; Genetic Transcription; Glaucoma; Goals; Growth Cones; Human; Injury; Knowledge; Lipids; Low Density Lipoprotein Receptor; Mammals; Measures; Mediating; Mediator of activation protein; Medical; Metabolic Pathway; Modeling; Mus; Natural regeneration; Neuraxis; Optic Nerve; Optic Nerve Injuries; Organism; Pathology; Pathway interactions; Patients; Pharmacology; Pre-Clinical Model; Process; Protein Import; Protein Isoprenylation; Proteins; Recovery; Recycling; Regenerative Medicine; Regulation; Reporter; Retinal Ganglion Cells; Role; SET gene; Signal Pathway; Source; Synapses; System; Testing; Time; Tissue-Specific Gene Expression; Transgenic Organisms; Translating; Ubiquinone; United States; Up-Regulation; Vision; Visual; Visual system structure; Zebrafish; antagonist; axon injury; axon regeneration; cell injury; chemical genetics; cholesterol trafficking; cost; critical period; differential expression; experimental study; extracellular; gain of function; glycosylation; improved; in vivo; in vivo Model; innovation; knock-down; laser capture microdissection; loss of function; mevalonate; mouse model; negative affect; nerve injury; neuroprotection; novel; novel therapeutics; optic nerve disorder; optic nerve regeneration; overexpression; pre-clinical; prophylactic; receptor expression; relating to nervous system; response; sight restoration; success; teleost fish; tool; transcriptome; transcriptome sequencing; transcriptomics

PROJECT SUMMARY Loss of vision due to optic neuropathies, like glaucoma, is a common cause of blindness in the United States. Unfortunately, these conditions are usually permanent because the central nervous system lacks the ability to regenerate damaged axons. Mammalian models of optic nerve (ON) injury recapitulate the pathology seen in patients making it difficult to understand what is needed for successful regeneration. In contrast, teleost fish, such as the zebrafish, can successfully regenerate damage to the ON and recover lost vision. We are using this organism to study the mechanisms of successful ON regeneration with the hopes of translating these findings into novel therapeutics to improve regeneration in mammalian disease models and patients. In a transcriptome- wide study of retinal ganglion cells (RGCs) during zebrafish ON regeneration we identified the mevalonate and cholesterol pathways as up regulated during this process. Our preliminary data suggests the master transcriptional regulator of these pathways, srebf2, is necessary for successful ON regeneration. We hypothesize that srebf2 mediates ON regeneration by activating the RGC intrinsic mevalonate and cholesterol synthesis pathway and/or inducing expression of receptors for extracellular sources of cholesterol and lipids. Using the powerful genetic and chemical tools available for the zebrafish system, we propose to identify the critical period of srebf2 activity and the downstream mediator(s) of its function. Aim 1 will determine when srebf2 function in RGCs is critical for ON regeneration and using novel reporter lines of srebf2 activity to delineate when transcriptional activity occurs. We will also test if activation of srebf2 activity is sufficient to accelerate ON regeneration. Lastly, we will use laser capture microdissection RNA-seq (LCM-seq) to identify differential gene expression under gain- and loss-of-srebf2 function in RGCs. Aim 2 proposes to identify which RGC intrinsic or extrinsic pathways downstream of srebf2 mediate its function. We will use combinations of drugs and gene knockdown to determine if intrinsic mevalonate/cholesterol synthesis and external supplies are independent, interdependent, and/or compensatory for successful ON regeneration. Depending upon the results of this study we will further examine the downstream intrinsic synthesis pathways for cholesterol, ubiquinone, protein prenylation, and protein N-glycosylation or low-density lipoprotein receptors and their downstream processing. Aim 3 will test the sufficiency of Srebf2 expression to provide neuroprotection and stimulate axon regeneration in a mouse model of acute ON injury. LCM-seq will be used to identify gene expression changes induced in mouse RGCs by Srebf2 and compared to those identified in zebrafish to suggest mechanisms for success or failure. These experiments will delineate the pathways downstream of srebf2 necessary for efficient ON regeneration and suggest paths forward to enhance mammalian regeneration.

项目摘要 视力丧失因青光眼等视力，是美国失明的常见原因。 不幸的是，这些情况通常是永久的，因为中枢神经系统缺乏能力 再生受损的轴突。视神经（ON）损伤的哺乳动物模型概括了 患者很难理解成功再生所需的东西。相比之下，硬骨鱼， 例如斑马鱼，可以成功再生对ON的损害并恢复失去的视力。我们正在使用这个 有机体研究成功再生的成功机制，以转化这些发现 进入新的治疗剂，以改善哺乳动物疾病模型和患者的再生。在转录组中 - 斑马鱼期间对视网膜神经节细胞（RGC）的广泛研究，我们确定 在此过程中，胆固醇途径如调节。我们的初步数据表明大师 这些途径的转录调节因子SREBF2对于成功再生是必要的。我们假设 SREBF2通过激活RGC固有的Mevalonate和胆固醇合成而导致再生介导 胆固醇和脂质细胞外源的受体表达的途径和/或诱导表达。使用 斑马鱼系统可用的强大遗传和化学工具，我们建议确定关键时期 SREBF2活性及其功能的下游介体。 AIM 1将确定SREBF2何时在 RGC对于再生和使用SREBF2活性的新闻记者线至关重要 转录活动发生。我们还将测试SREBF2活性的激活是否足以加速 再生。最后，我们将使用激光捕获显微解剖RNA-seq（LCM-Seq）来识别差异基因 在RGC中的增益和S-REBF2功能下的表达。 AIM 2建议确定哪种RGC内在或 SREBF2下游的外部途径介导了其功能。我们将使用药物和基因的组合 敲低以确定固有的甲戊酸/胆固醇合成和外部供应是否是独立的， 相互依存的和/或补偿性成功。取决于这项研究的结果 我们将进一步研究胆固醇，泛氨酮，蛋白质的下游固有合成途径 特点化和蛋白质N-糖基化或低密度脂蛋白受体及其下游加工。 AIM 3将测试SREBF2表达的充分性，以提供神经保护并刺激轴突再生 在急性的小鼠模型中受伤。 LCM-seq将用于识别诱导的基因表达变化 srebf2的小鼠RGC与斑马鱼中鉴定的小鼠RGC提出了成功或 失败。这些实验将描绘出有效效率所需的SREBF2下游的途径 再生并提出前进的路径，以增强哺乳动物的再生。